Clinical Research Directory
Browse clinical research sites, groups, and studies.
RSV Vaccine in Transplant Recipients
Sponsor: University Health Network, Toronto
Summary
Adjuvant, non-live RSV vaccine will be administered to adult lung and allogeneic hematopoietic stem cell transplant recipients. The safety and immunogenicity of this intervention will be studied. Blood work will be collected before and after the intervention, to assess humoral and cellular immunity. Participants will be followed for adverse reaction, hospitalization, RSV breakthrough infection, graft rejection or graft versus host disease. This study has Health Canada and UHN REB approval.
Official title: Safety and Immunogenicity of Non-live, Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine in Allogeneic Stem Cell Transplant and Lung Transplant Recipients
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2024-10-01
Completion Date
2026-03
Last Updated
2025-11-26
Healthy Volunteers
No
Interventions
Adjuvant, non-live RSV vaccine
One dose of arexvy vaccine to transplant recipients.
Locations (1)
University Health Network
Toronto, Canada